Discover how Lonza Bioscience Solutions supports drug development with its integrated portfolio of primary human cells, media, and reagents. Learn from Lonza scientists how these tools enable the creation of advanced in vitro models, enhancing biological relevancy and reducing reliance on animal testing.
Lonza Bioscience Solutions provides life science researchers with the tools they need to develop and test critical disease-treating drugs and therapies, from basic research to final product release. Lonza provides an integrated portfolio of primary cells, media and reagents, to support drug discovery and preclinical pharmaceutical work flow for toxicity and safety testing to better understand the pharmacokinetics and metabolism of new compounds.
We will review our portfolio of primary human cells and optimized media systems and custom services for tissue acquisition, isolation, and production. You will learn from Lonza scientists how our products can be the building blocks for the development of advanced complex in vitro models to provide improved biological relevancy and predictivity to aid in reducing the reliance on animal testing.
Key Topics Include:
- Receive an introduction to how primary cells and media can be utilized for optimized screening and testing
- Learn how biologically-relevant and predictive models can be built using the co-culture of primary cells
- Understand the benefits of 3D cell models
Presenters
Associate Director, Marketing Strategy
Kevin has a long history in the life sciences industry having worked in technical product support, product management and marketing at several key suppliers such as Lonza, ATCC, and Life Technologies. He is currently focused on developing Lonza’s participation in the drug discovery market for small molecules. In all his roles, Kevin’s main objective has always been to assist researchers in being more productive by providing tools and solutions that meet the constantly changing market needs.
Principal Scientist
Lonza
Manisha is an interdisciplinary scientist with extensive experience in in vitro assay development for drug discovery and pre-clinical drug-safety studies. Her area of expertise includes the application of mammalian cell and organotypic culture models integrating high-throughput analytical approaches with novel in vitro platforms to solve drug safety problems in drug-induced liver injury and liver diseases. She currently leads several R&D innovation projects to support and expand Lonza’s primary cell, assay and media portfolio within Cell Discovery R&D at Lonza Biosciences.
Production Partner
Lonza Bioscience
Lonza is one of the world’s largest contract development and manufacturing organizations (CDMOs) dedicated to serving the healthcare industry. Working across five continents, our colleagues work alongside pharma and biotech companies to turn their breakthrough innovations into viable therapies. We support our customers in bringing life-saving and life-enhancing treatments to patients worldwide with a combination of cutting-edge science, smart technology and lean manufacturing.
Additional Content From Lonza Bioscience
Building New Approach Methodologies for Angiogenesis and Vascularized Models
Join us for an insightful webinar exploring Lonza’s comprehensive portfolio of primary human cells and optimized media systems.
Advances in Preclinical Research using Human Co-culture Models: Applications in Immunology, Infectious Disease, and Oncology
Join Dr. Ethan Shelkey as he discusses human primary co-culture models with immune cells that are used in infectious disease studies and cancer therapeutic testing.
Cell-Based Assays for Immuno-oncology
Join Lonza scientist Ethan Shelkey as he explores how cell-based assays can assess immune activation and support immunotherapy development.
Additional Content From Scientist.com
How to Avoid Expensive Redesign Cycles in Antibody Discovery
Learn how integrated antibody discovery and engineering strategies can accelerate the path from hit to optimized lead in less than 12 months while minimizing costly redesign cycles.
Beyond Exposure: Integrating PK/PD for Translational Predictive Power
Learn to integrate PK/PD modeling and strategic biomarkers to bridge the translational gap. Improve clinical predictability for NCEs, ADCs, and large molecules in this technical webinar.
Advancing the Manufacture of Mesenchymal Stromal Cells and Derived Extracellular Vesicles in Stirred-Tank Bioreactors Through Enhanced Bioprocess Control
Learn how to scale the production of MSCs and extracellular vesicles using bioreactor control and real-time monitoring for more consistent therapies.
Related Content
From Clinical Data to Actionable Assets for Pharmaceutical R&D
In this webinar, learn to transform raw clinical and biobanking data into research-ready assets to accelerate pharmaceutical R&D.
Improving Preclinical Decision-Making in Obesity and CKD with Translational In Vivo Phenotyping
Join us to learn how in-depth in vivo phenotyping using patient-relevant models can improve preclinical decision-making.